Inactivation of the retinoblastoma protein pathway is the most common abnormality in malignant tumors. We therefore tried to detect agents that induce the cyclindependent kinase inhibitor p15
Introduction
Cell cycle regulation is important in growth control, and therefore the deregulation of cell cycle machinery has been implicated in carcinogenesis (1) . Cyclins and cyclindependent kinases (CDK), in association with each other, play key roles in promoting the G 1 -to-S phase transition of the cell cycle by phosphorylating the retinoblastoma (RB) protein (2, 3) . Activation of cyclin-CDK complexes is counterbalanced by CDK inhibitors including the INK4 family. The INK4 family consists of p15(EGFR) phosphorylation and its downstream pathways such as phosphatidylinositol 3 ¶-kinase (PI3K)-Akt and MAPK/ERK cascades, resulting in inhibition of proliferation in tumor cell lines (20 -22) . EGFR is expressed in most human tissues and is often highly expressed in human solid tumors (23, 24) . However, the level of EGFR expression alone is not sufficient to predict the response of tumor cells to ZD1839 (25, 26) . Several groups have shown that ZD1839 effectively induces a marked response in patients with non -small-cell lung cancer who have somatic mutations in exons 18 to 21 in the ATP-binding region of the EGFR kinase domain (27 -29) . These findings indicate that EGFR mutations might be a determinant of ZD1839 sensitivity in non -small-cell lung cancer. On the other hand, activating EGFR mutations are rare in colorectal cancer, and patients whose colorectal cancer possessed no EGFR mutations experienced disease regression following treatment with ZD1839 and chemotherapy (30) . Therefore, other downstream events may influence responsiveness to EGFR inhibition.
We here show that ZD1839 induces p15
INK4b by inhibiting ERK phosphorylation, and that p15
INK4b status is at least partially associated with ZD1839 sensitivity. We suggest for the first time that the ability of ZD1839 to induce p15
INK4b by inhibiting signals through the MAPK/ ERK pathway could be one of the mechanisms of the antiproliferative activity of this agent.
Materials and Methods
Cell Culture and Reagents Human immortalized keratinocyte HaCaT cells (a kind gift from Dr. N.E. Fusenig, German Cancer Research Center, Heidelberg, Germany) and human colon cancer cell lines (HT-29 and Colo320DM) were maintained in DMEM containing 10% fetal bovine serum, 2 mmol/L glutamine, and antibiotics (penicillin/streptomycin), and were incubated at 37jC in a humidified atmosphere with 5% CO 2 . Wild-type and p15
INK4b -deficient [p15(À/À)] mouse embryo fibroblasts (MEF; ref. 9; a kind gift from Dr. Paul Krimpenfort, Division of Molecular Genetics and Centre of Biomedical Genetics, Netherlands Cancer Institute, Amsterdam, the Netherlands) were maintained in DMEM supplemented with 10% fetal bovine serum, 2 mmol/L glutamine, 0.1 mmol/L MEM nonessential amino acids, 55 mmol/L 2-mercaptoethanol, and antibiotics (penicillin/streptomycin), and incubated at 37jC in a humidified atmosphere of 9% CO 2 . ZD1839 (Gefitinib, Iressa) was supplied by AstraZeneca. PD98059 (MEK inhibitor) and Akt-III (SH-6; Akt inhibitor) were purchased from Calbiochem. They were dissolved in DMSO and diluted to the final concentration in each volume of culture medium used.
Growth Inhibition Assay and Cell Cycle Analysis One day after inoculation of cells, various concentrations of ZD1839, PD98059, or Akt-III were added to the culture medium. The number of viable cells was counted 24 to 48 h after drug addition with the trypan blue dye exclusion test. For flow cytometry analysis, unsynchronized HaCaT cells were exposed to the agents for the indicated times. The cells were then treated with Triton X-100 and RNase A, and their nuclei were stained with propidium iodide before DNA content was measured using a Becton Dickinson FACSCalibur. At least 10,000 cells were counted and the ModFit LD V2.0 software package (Becton Dickinson) was used to analyze the data.
RNA Isolation and Northern Blot Analysis Total RNA was isolated using a Sepasol RNA isolation kit (Nacalai Tesque, Inc.) and poly(A)+ mRNA was separated from 200 Ag of total RNA using an Oligotex-dT30 (Super) mRNA purification kit (Takara Bio, Inc.). Poly(A)+ mRNA was fractionated on 1% agarose gels, transferred to nylon filters, and probed according to standard procedures. Exon 1 of p15 cDNA was used as a probe. Northern blot analysis was done using standard methods (31) . For mRNA half-life studies, 5 Ag/mL actinomycin D (Sigma) was added directly to the medium. The relative band intensity was assessed by densitometric analysis of digitalized autographic images using Scion Image software (Scion Corp. ) antibody (phospho-Akt Pathway Sampler Kit, Cell Signaling Technology, Inc.), and a-tubulin antibody (Oncogene Research Products). The signal was then developed with an enhanced chemiluminescence system (Amersham Pharmacia Biotech, UK Ltd.).
Cell Viability Assay Cells were seeded at 4,000 per well in 96-well plates. The number of viable cells was determined by Cell Counting Kit-8 assay according to the manufacturer's instructions (Dojindo, Kumamoto, Japan). After incubation with the indicated concentrations of ZD1839 or PD98059, kit reagent WST-8 was added to the medium and incubated for a further 1 h. The absorbance of samples (450 nm) was determined using a scanning multiwell spectrophotometer that serves as an ELISA reader.
Statistical Analysis Statistical evaluation of the data was done using the Student's t test for simple comparison between groups and treatments. P < 0.05 was considered statistically significant.
Results

Cell Growth Inhibition and G 1 Arrest by ZD1839 in HaCaT Cells
We first investigated the antiproliferative effects of ZD1839 in human immortalized keratinocyte HaCaT cells. We observed that ZD1839 inhibits the growth of HaCaT cells in a dose-dependent manner and 600 nmol/L ZD1839 had a cytostatic effect (Fig. 1A) . To examine the effects of ZD1839 on cell cycle progression, the DNA content of the cell nuclei was measured by flow cytometry analysis. The treatment with 600 nmol/L ZD1839 increased the percentage at the G 1 phase and decreased that at the S phase in a time-dependent manner (Fig. 1B) . These data show that ZD1839 arrests the cell cycle of HaCaT cells at the G 1 phase.
p15 INK4b Induction and RB Hypophosphorylation by ZD1839 in HaCaT Cells
We tried to elucidate whether the expression of p15 was markedly increased at 24 h or more after treatment with ZD1839 in a time-dependent manner, compared with the treatment with solvent DMSO alone (Fig. 1C) . These results suggest that p15 INK4b is an important molecular target of ZD1839 among the INK4 family, whose members are associated with G 1 cell cycle arrest. There were no obvious changes in the abundance of other INK4 family members such as p16 INK4a , p18
INK4c
, and p19 INK4d ; however, the expression of p21 WAF1 and p27 KIP1 was slightly up-regulated after treatment with ZD1839 as previously reported (32, 33) . The protein p15
INK4b is a specific inhibitor of cyclin D -dependent kinases and the subsequent dephosphorylation of the RB protein causes G 1 cell cycle arrest. We therefore examined whether ZD1839 could alter the phosphorylation status of the RB protein in HaCaT cells. A hyperphosphorylated form of the RB protein (ppRB) was converted into a hypophosphorylated form (pRB) 24 to 48 h after the treatment (Fig. 1C) mRNA was up-regulated at 12 h or more after treatment with ZD1839 in a time-dependent manner ( Fig. 2A) . The longer transcript of p15
INK4b mRNA is f3.2 kb and the shorter transcript is f2.2 kb. These two transcripts were detected in a previous report (13) . Because we found that p15
INK4b mRNA is induced by ZD1839, we evaluated the effect of ZD1839 on the promoter activity in a p15 INK4b promoter-luciferase fusion plasmid by transient assay (18) . However, we did not detect significant up-regulation of the p15
INK4b promoter by ZD1839 INK4b mRNA levels were examined by Northern blot analysis. The half-life of p15
INK4b mRNA was calculated to be 1.6 h in control cells. On the other hand, in cells treated with ZD1839, the half-life of p15
INK4b mRNA increased f2-fold (3.2 h; Fig. 2B ). These results suggest that an increase of p15
INK4b mRNA stability could at least partially contribute to the up-regulation of p15
INK4b by ZD1839.
Effects of ZD1839 on the Expression of Cell Cycle Regulatory Molecules in HaCaT Cells
We examined the effects of ZD1839 on the expression of cell cycle regulatory molecules in HaCaT cells. The time course study indicated that cyclin D1 and its transcription factor c-myc were down-regulated 12 h after treatment with ZD1839 (Fig. 3) . Moreover, we investigated the effects of ZD1839 on the phosphorylation of EGFR downstream molecules, Akt and ERK, in HaCaT cells. The time course study indicated that ERK phosphorylation was down-regulated 12 h after treatment with ZD1839; however, no apparent change in phosphorylation of Akt and its downstream molecule GSK3h was observed (Fig. 3) . These results suggest that the inhibition of ERK phosphorylation is involved in ZD1839-mediated cell cycle arrest of HaCaT cells.
Effects of Inhibiting Downstream Signals of EGFR
The MAPK/ERK and PI3K-Akt pathways are two main signaling pathways downstream of EGFR. We examined the effects of MEK inhibitor PD98059 and Akt inhibitor Akt-III on the cell cycle regulation and p15
INK4b induction in HaCaT cells. Both agents inhibited the cell growth in a dose-dependent manner (Fig. 4A ) and increased the percentage at the G 1 phase and decreased that at the S phase, respectively (Fig. 4B) . We then did Western blot analysis 48 h after treatment with 40 Amol/L PD98059 or 20 Amol/L Akt-III. PD98059 induced p15
INK4b and p27 KIP1 and down-regulated c-myc. This pattern of the expression profile is similar to that observed with ZD1839 (Figs. 1C,  3 , and 4C). Akt-III increased p21 WAF1 and p27 KIP1 and decreased cyclin D1 expression; however, unlike PD98059, Akt-III did not induce p15
INK4b (Fig. 4C) . These results suggest that p15
INK4b induction is associated with the inhibition of the MAPK/ERK pathway in HaCaT cells.
Association between p15 INK4b or ERK Phosphorylation Status and the Antiproliferative Effects of ZD1839
To reveal whether p15 INK4b contributes to the antiproliferative activity of MEK inhibitor as a result of the inhibition of ERK phosphorylation, we did the Cell Counting Kit-8 assay to assess the viability of wild-type and p15
INK4b -deficient [p15(À/À)] MEFs treated with PD98059. The p15(À/À) MEFs exhibited decreased PD98059 sensitivity relative to wild-type MEFs (Fig. 5A) . To analyze the physiologic relevance of the induction of p15
INK4b in ZD1839-induced growth inhibition, we next examined the effects of ZD1839 on the cell growth of wildtype and p15(À/À) MEFs. As expected, the p15(À/À) MEFs grew more rapidly than wild-type MEFs in the absence of ZD1839. The p15(À/À) MEFs were also more resistant to the growth inhibitory effects of ZD1839 than were wild-type MEFs, and 2 Amol/L ZD1839 had a cytostatic effect in wild-type MEFs (Fig. 5B and C) .
Furthermore, we found that ERK phosphorylation was inhibited in both types of MEFs; however, p15
INK4b protein induction by treatment with ZD1839 was detected only in wild-type MEFs (Fig. 5D) .
To assess the influence of the activation status of ERK on ZD1839-mediated cell growth inhibition, we evaluated the antiproliferative effects of ZD1839 in two human colon cancer cell lines, HT-29 and Colo320DM (Fig. 6A) . The graph shows that the growth of HT-29 cells was inhibited in a dose-dependent manner; however, that of Colo320DM cells was not inhibited by ZD1839. To investigate whether the difference in growth inhibition by ZD1839 between the two cell lines depends on ERK phosphorylation and p15
INK4b induction, we did Western blot analysis. The level of ERK in Colo320DM cells was higher than that in HT-29 cells; however, constitutive phosphorylation of ERK was not observed in Colo320DM cells (Fig. 6B) . Moreover, p15
INK4b induction and the inhibition of ERK phosphorylation by ZD1839 were detected only in HT-29 cells. Taken together, these results suggest that loss of p15
INK4b influences the cellular response to the antiproliferative effects of ZD1839 and that, in addition to induction of p15 INK4b , status of ERK phosphorylation and inactivation of the MAPK/ERK pathway play important roles in the cell growth inhibition induced by ZD1839.
Discussion
A great number of cancer studies have shown that the RB pathway is the most frequently inactivated in human malignant tumors (6, 7) . If the RB pathway is inactivated, activation of the INK4 family leads to functional restoration of this pathway. Interestingly, it has been reported that ZD1839 induces p21 WAF1 and p27 KIP1 (32, 33) and imatinib mesylate (STI571, Gleevec) upregulates p18 INK4c (34) , resulting in hypophosphorylation of the RB protein.
In the present study, we disclosed that ZD1839 upregulates p15
INK4b protein and subsequently converts a , p27 KIP1 , p-ERK1/2, ERK1/2, p-Akt, Akt, CDK4/6, cyclin D1, and c-myc proteins were examined by Western blotting. a-Tubulin was chosen as the loading control in all blots. be most effective against tumors with activated Akt; however, they found no correlation between activated ERK status and effectiveness of ZD1839. On the other hand, Ono et al. (43) indicated that high sensitivity to ZD1839 in cancer cell lines is closely correlated with dependence not only on Akt but also on ERK activation for cellular survival and proliferation. In our study, we showed that ZD1839 inhibited ERK phosphorylation but did not block Akt phosphorylation in HaCaT cells (Fig. 3) . These results suggest that inhibition of ERK phosphorylation plays an important role in ZD1839-mediated cell cycle arrest. Furthermore, we found that the status of ERK phosphorylation and p15
INK4b induction through inhibition of ERK phosphorylation are involved in the antiproliferative activity of ZD1839 (Fig. 6A and B) . Ogino et al. (30) reported that EGFR mutations are uncommon in colorectal cancer, and therefore other downstream molecules may influence responsiveness to EGFR inhibition. Taken together, our results may suggest that p15
INK4b induction through inhibition of ERK phosphorylation is associated with the antiproliferative effects of ZD1839.
Our results have suggested that ZD1839 induces p15
INK4b through inhibition of ERK phosphorylation, resulting in hypophosphorylation of the RB protein. Therefore, anticancer agents activating RB function, such as ZD1839, may contribute to new strategies for the therapy of malignancies, which we have termed ''gene-regulating chemotherapy'' (44, 45) . A common strategy to detect a novel molecular-targeting anticancer agent has been based on finding direct inhibitors of various malignancy-related molecules in in vitro conditions. On the other hand, using the screening system we established, we were able to identify several p15 INK4b -inducing agents containing ZD1839. This suggests that INK4 family -inducing agents, toward activation of RB function, will be useful as new molecular-targeting anticancer drugs against malignant tumors.
